# Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

> **NCT00276796** · PHASE2 · COMPLETED · sponsor: **Gynecologic Oncology Group** · enrollment: 66 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** paclitaxel
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00276796
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2013-05-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276796, "Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00276796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*